Tvardi Therapeutics to Participate at the Cowen 44th Annual Health Care Conference
Tvardi Therapeutics, Inc. ("Tvardi"), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced it will participate at the Cowen 44th Annual Health Care Conference with the management team holding one-on-one investor meetings on March 4, 2024.
Cowen's 44th Annual Health Care Conference is taking place March 4 - 6, 2024, at the Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats, and innovative panel discussions hosted by members of the Cowen research team that focus on various aspects of the health care industry.
About Tvardi Therapeutics
Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company is conducting Phase 2 clinical trials in STAT3-driven diseases: hepatocellular carcinoma (NCT05440708) and idiopathic pulmonary fibrosis (NCT05671835). To learn more, please visit tvardi.com or follow us on LinkedIn and X (Twitter).
RiskOpsAItm, the Award Winning Pioneer in AI Driven Integrated Risk Modeling & Decision Supremacy, hosts Ethical Dimensions of AI: A Deep Dive into Data Privacy and Security.
"We are delighted...
Landlord Studio, the leading property management accounting software for self-managing landlords announced its new free listing syndication feature in partnership with Zillow and Zumper.
Charles Chan, CEO of Landlord Studio said, "We're delighted to...
TIER IV, a pioneer in open-source autonomous driving (AD) technology, today announced an exciting initiative aimed at shaping the future of highway trucking. In response to driver shortage challenges facing Japan's cargo industry, the company is set...
FLJ Group Limited (the "Company"), today announced that it has received a letter dated April 25, 2024 (the "Determination Letter") from the listing qualifications department staff (the "Staff") of The Nasdaq Stock Market ("Nasdaq"), notifying that...
watchTowr, a leader in external attack surface management (EASM) technology and fuelled by watchTowr Labs, a renowned vulnerability R&D capability, has formed a strategic partnership with JupiterOne. JupiterOne is a leader in cyber asset attack...
Premia Partners, a leading ETF provider from Hong Kong, announces today fee reduction of its Premia Vietnam ETF (the ETF) and change of the underlying index to S&P Vietnam Core Index (USD) NTR (the index) with immediate effect.
Total expense ratio...
